financetom
Business
financetom
/
Business
/
Alphabet's Google Moves Gemini App Team Under DeepMind Group
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alphabet's Google Moves Gemini App Team Under DeepMind Group
Oct 18, 2024 4:56 AM

07:27 AM EDT, 10/18/2024 (MT Newswires) -- Alphabet (GOOG, GOOGL) said in a Thursday blog that its Gemini app team will join the group behind its artificial intelligence research lab Google DeepMind to simplify its structure.

Gemini app is the group's direct consumer interface, according to the blog.

The company said it expects the move to accelerate deployment of new models in the Gemini app and improve feedback loops, among others.

Price: 165.06, Change: +0.55, Percent Change: +0.33

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday that its experimental ARV-393 showed significant single-agent activity in a certain type of cell lymphoma, based on data from preclinical studies. The results cover activity in patient-derived xenograft model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type and PDX models of transformed follicular lymphoma. When combined with oral...
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Friday that initial results from its ongoing long-term open-label trial of navenibart in hereditary angioedema showed a significant reduction in monthly attack rates, supporting the potential for dosing schedules of every three or six months. The biopharmaceutical company said navenibart demonstrated an overall attack-freedom of 50% over...
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial
Jun 13, 2025
07:45 AM EDT, 06/13/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said updated results from 17 patients in its phase 1/2 BEACON trial evaluating BEAM-101, a base-editing therapy for severe sickle cell disease, showed robust and durable increases in fetal hemoglobin, reduced sickle hemoglobin, and normalized hemolysis markers. The company will present the new safety and efficacy data at...
Copyright 2023-2026 - www.financetom.com All Rights Reserved